09:50 AM EST - ProMIS Neurosciences, Inc. : Announced the identification of several potential antibody therapeutic candidates aimed at selectively targeting toxic oligomers of the protein synuclein, considered a root cause of Parkinson's disease. ProMIS Neurosciences, Inc.
shares T.PMN are trading up $0.02 at $0.31.
